BRIANNA LAFFERTY: Open Payments
NPI 1003545542 · DURAND, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$480 in 25 payments from 10 companies in 2025. Trend: 2023 $619 · 2024 $514 · 2025 $480
Food & beverage: $480
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $117 |
| ABBVIE INC. | 4 | $75 |
| AstraZeneca Pharmaceuticals LP | 4 | $61 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $52 |
| Lilly USA, LLC | 3 | $47 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Exact Sciences Corporation | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
Products named: Ozempic, REXULTI, CAPLYTA, MOUNJARO, AIRSUPRA, Wegovy, VRAYLAR, UBRELVY.
Industry payments across MI — which companies pay providers there.
